Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Fabiana Gentilini"'
Autor:
Fabiana Gentilini, Anna Levi, Vincenzo Federico, Eleonora Russo, Robin Foà, Maria Teresa Petrucci
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 4, Iss 1, Pp e2012035-e2012035 (2012)
Introduction: Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow micro-environment. Intravenous Bortezomib (1.3 mg/m2 administered on days 1,4,8 and 11 of a 21 day cycle), with or without dexamethasone, is effective an
Externí odkaz:
https://doaj.org/article/942f1d881d474cd8801b8f4085d31465
Autor:
Massimo Breccia, Giuseppe Cimino, Daniela Diverio, Fabiana Gentilini, Franco Mandelli, Francesco Lo Coco
Publikováno v:
Haematologica, Vol 92, Iss 9 (2007)
We report here a preliminary experience with gemtuzumab ozogamicin (GO) used at low dosage (3 mg/m2) in 3 elderly patients with acute promyelocytic leukaemia (APL) who presented molecular relapse and were unfit for intensive chemotherapy.
Externí odkaz:
https://doaj.org/article/0c6bfe9ee05a4ad4ba98479c2a2e06fe
Publikováno v:
Recenti progressi in medicina. 109(12)
Immunotherapy is a novel treatment strategy that, even though implemented decades ago, has emerged with important clinical data in the last 10 years and is fulfilling the promise of prolonging survival in several types of cancer by restoring the immu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::93c4e6fa1b328cb1fea25a05398523fc
https://pubmed.ncbi.nlm.nih.gov/30667385
https://pubmed.ncbi.nlm.nih.gov/30667385
Autor:
Massimo Breccia, Nicola Di Renzo, Fabio Stagno, Raffaele Porrini, Ginny P Sen, Francesco De Solda, Mariella D'Adda, Ester Pungolino, Elisabetta Abruzzese, Alberto Bosi, Fabrizio Pane, Federica Sorà, Ester Orlandi, Fabiana Gentilini, Anna Marina Liberati, Carlo Gambacorti-Passerini
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases
Mediterranean Journal of Hematology and Infectious Diseases, Vol 11, Iss 1 (2019)
Mediterranean Journal of Hematology and Infectious Diseases, Vol 11, Iss 1 (2019)
Background and Objectives While tyrosine kinase inhibitors (TKIs) have transformed CP-CML management, limited data exist on their use in clinical practice. Methods SIMPLICITY (NCT01244750) is an observational study in CP-CML patients, exploring first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61ee7c4b52dfbf87430567094b8978ed
https://doi.org/10.4084/mjhid.2019.025
https://doi.org/10.4084/mjhid.2019.025
Autor:
Claudia Crippa, Alessandra Romano, Michele Cavo, Francesca Elice, Roberto Marasca, Mario Boccadoro, Massimo Offidani, Renato Zambello, Claudia Cellini, Valeria Magarotto, Vincenzo Callea, Monica Galli, Claudia Polloni, Patrizia Tosi, Angelo Michele Carella, Giulia Benevolo, Elena Zamagni, Andrea Evangelista, Fabiana Gentilini, Stefano Pulini, Antonio Palumbo, Vittorio Montefusco, Sara Bringhen, Chiara Nozzoli, Davide Rossi, Norbert Pescosta, Roberto Ria, Paola Tacchetti, Francesca Patriarca, Luca Baldini, Tommaso Caravita, Fortunato Morabito
Publikováno v:
Journal of Clinical Oncology. 29:986-993
Purpose In patients with myeloma, thalidomide significantly improves outcomes but increases the risk of thromboembolic events. In this randomized, open-label, multicenter trial, we compared aspirin (ASA) or fixed low-dose warfarin (WAR) versus low mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10aaae7aa43cd797d92d93df9cdbdcd9
https://doi.org/10.1200/jco.2010.31.6844
https://doi.org/10.1200/jco.2010.31.6844
Autor:
Angela Matturro, Robin Foà, Lavinia Grapulin, Federico De Angelis, Elena Cavalieri, Alessandro Pulsoni, Marco Vignetti, Fabiana Gentilini, Mikael Sacco, Fabio Torelli, Giorgia Annechini, Franco Mandelli, Natalia Frattarelli
Publikováno v:
Leukemia & Lymphoma. 50:1803-1808
The BEACOPP regimen is a consolidated first-line treatment regimen for advanced stage Hodgkin lymphoma (HL), while few data are available on the efficacy of this regimen in advanced disease. About 50% of patients with HL relapsed after or refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d204599a03b251294e6cee219a1da01
https://doi.org/10.3109/10428190903254383
https://doi.org/10.3109/10428190903254383
Autor:
Gregorio Antonio Brunetti, Marta Chisini, Maria Teresa Petrucci, Fabiana Gentilini, Claudio Cartoni, Paola Finsinger, Roberto Foa
Increasing evidence from clinical studies demonstrates the efficacy of bendamustine as first-line treatment of multiple myeloma (MM) patients [1], as well as in heavily pre-treated relapsed/refract...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a307ec4f87464915fa0e820d394bcf5
http://hdl.handle.net/11573/859628
http://hdl.handle.net/11573/859628
Autor:
Alessandro Gozzetti, Alfonso Cerase, Flavia Lotti, Davide Rossi, Antonio Palumbo, Maria Teresa Petrucci, Francesca Patriarca, Chiara Nozzoli, Massimo Offidani, Michele Floridia, Salvatore Berretta, Roberto Vallone, Pellegrino Musto, Francesco Lauria, for the GIMEMA Myeloma Working Party, additional authors who participated to the study: Elena Marchini, Alberto Fabbri, Stefania Oliva, Fabiana Gentilini, Stelvio Ballanti, Giuseppe Mele, Monica Galli, Maria Teresa Pirrotta, Francesco Di Raimondo, CAVO, MICHELE, ZAMAGNI, ELENA
BACKGROUND: Intracranial involvement in multiple myeloma is extremely rare. The effect of new drugs (eg, thalidomide, bortezomib, lenalidomide) with respect to old drugs (eg, alkylators, steroids) has not been reported. METHODS: We collected clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00cf17fa07f69ea6feabf78e5b71a343
http://hdl.handle.net/11585/118925
http://hdl.handle.net/11585/118925
Publikováno v:
Patient preference and adherence
The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4bd9bb809c14baf7aad0d52d7b56dae
https://pubmed.ncbi.nlm.nih.gov/25045252
https://pubmed.ncbi.nlm.nih.gov/25045252
Autor:
Pieter Sonneveld, Concetta Conticello, Massimo Offidani, Valeria Magarotto, Stefania Oliva, Fabiana Gentilini, Sara Bringhen, Luana Boccadifuoco, Mario Boccadoro, Vittorio Montefusco, Pellegrino Musto, Giulia Benevolo, Davide Rossi, Maria Teresa Petrucci, Alessandra Larocca, Paola Omedè, Paola Tacchetti, Tommaso Caravita, Giovannino Ciccone, Antonio Palumbo, Mariella Genuardi
Publikováno v:
Blood, 124(1), 63-69. American Society of Hematology
This multicenter, open-label phase 2 trial determined the safety and efficacy of carfilzomib, a novel and irreversible proteasome inhibitor, in combination with cyclophosphamide and dexamethasone (CCyd) in patients with newly diagnosed multiple myelo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e71bcd19684a8700500beb3bc854055
https://pure.eur.nl/en/publications/567b86bf-db82-4b0c-b25f-3c27f0a22eb5
https://pure.eur.nl/en/publications/567b86bf-db82-4b0c-b25f-3c27f0a22eb5